Europe Puts Renewed Emphasis on Patient Communication - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Europe Puts Renewed Emphasis on Patient Communication As pair of initiatives show, the clinical trials community in Europe is working harder to get its message across to its key partner: patients.

Source: Applied Clinical Trials

The clinical trials community in Europe is working ever harder to get its message across to its key partner: patients. The second workshop of the European Patients' Academy on Therapeutic Innovation (EUPATI), entitled "Reaching a Public Audience on Medicines Development," was held in Warsaw, Poland, earlier this month. In addition, the BBC has released a free video about the risks and ethical aspects of clinical trials.

The EUPATI workshop has been designed to draw on the group's social research work involving patients and citizens across Europe, as well as to hear views from patient advocates and the public and to provide details about successful examples of information sharing. EUPATI is funded by the Innovative Medicines Initiative (IMI), and aims to provide scientifically reliable, objective, and comprehensive information to patients on clinical research. The consortium's goal is to increase the capabilities of well-informed patients and patient organizations to be effective advocates in clinical research.

In a separate initiative, trial organizers have participated in a video that should help reassure patients after continued fallout from the 2006 clinical trial disaster involving six healthy volunteers at Northwick Park Hospital in London. In the incident, volunteers were treated for organ failure after experiencing a serious reaction within hours of taking the anti-inflammatory drug, TGN1412.

Such incidents are unlikely to happen again, according to experts quoted in a BBC article published last year. Things have changed, they said, since the release of the Duff Report, which was written in response to the Northwick Park trial. Among the changes is the U.K.'s Medicines and Health products Regulatory Agency (MHRA) now ensures that ethics committees look at preclinical data to decide whether the first dose given to humans is the right dose.

The BBC video begins with a news report about the Northwick Park disaster, before discussing the clinical trial process. To view the video, visit http://www.bbc.co.uk/learningzone/clips/clinical-trials-regulation-and-ethics/1465.html

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here